Personalis, Inc. PSNL

Tempus AI (NASDAQ:TEM) Founder and CEO Eric Lefkofsky said the company’s second-quarter performance was supported by continued demand for comprehensive genomic profiling and growth in its data-licensing business. Speaking at Morgan Stanley’s Global Healthcare Conference, Lefkofsky said the diagnost

Clarity on how much revenue Tempus AI will bring in through Medicare reimbursements for two of its cancer screenings appeased investors this week as shares surged Thursday. Tempus stock added 15% Thursday as part of a 36% advance over the last five sessions. in which Tempus is the third-largest position behind Tesla and SpaceX rose 4.3%.

Personalis holders receive Tempus shares worth $16.25 each under the pending merger

Tempus AI (NASDAQ:TEM) shares rose 2. 7% in pre-market trading following analyst actions from Piper Sandler and Canaccord Genuity as investors assessed the company’s pending acquisition of Personalis.

Tempus AI, Inc. (NASDAQ:TEM) rallied following a melanoma breakthrough reported by Moderna and Merck. The companies said their Phase 3 INTerpath-001 trial met its recurrence-free survival endpoint for the personalized cancer therapy intismeran autogene, also known as V940, combined with Keytruda. Detailed trial data remain pending. The read-through came from Personalis, which has supported the […]

Personalis (PSNL) has demonstrated exceptional momentum, gaining nearly 250% over the past year. Shares recently set a new 3-year high. PSNL stock maintains a 100% “Buy” technical opinion from Barchart. Despite strong price appreciation, PSNL remains unprofitable and highly speculative, with mixed analyst sentiment and significant short interest. Today’s Featured...

Healthcare stocks decreased late Monday afternoon, with the NYSE Healthcare Index and the State Stre

Tempus AI stock has surged over the past month, yet the valuation picture is split. The Discounted Cash Flow (DCF) intrinsic value estimate points to shares trading at a roughly 33.1% discount, while market based multiples lean expensive and the broader checks do not suggest a clear bargain. Tempus AI has returned about 54.8% over the past month, which puts extra focus on whether that jump is already pricing in much of the good news. The positive cancer vaccine trial linked to its planned...

In recent days, investors have reacted to phase 3 INTerpath-001 trial results showing a customized mRNA-based melanoma treatment improved recurrence-free survival, while also focusing on Tempus AI’s pending US$1.50 billion acquisition of Personalis Inc. as a move deeper into cancer genomics. Together, the trial success and acquisition plan highlight how Tempus AI is tying advanced mRNA oncology research to its broader precision medicine and data-driven cancer testing ambitions. We’ll now...

Tempus AI (TEM) is back in focus after investors linked a major melanoma trial milestone to its pending US$1.5b acquisition of Personalis Inc, raising fresh questions about how this cancer data deal fits the stock’s story. See our latest analysis for Tempus AI. At a latest share price of US$72.69, Tempus AI has seen strong short term momentum, with a 30 day share price return of 54.79% and a 90 day share price return of 57.41%. However, the 1 year total shareholder return is down 9.72%,...

BTIG analyst Mark Massaro raised the firm’s price target on Tempus AI to $80 from $70 and kept a Buy rating.

Tempus AI wrote a $1.5 billion check for a genomics company most investors had never heard of, and one blockbuster clinical trial announcement just changed everything about how that deal looks.

TEM stock rose as investors connected the upbeat clinical results to Tempus’s planned $1.5 billion acquisition of Personalis, announced last month.

TEM raises its 2026 revenue outlook as oncology testing, data demand and FDA-linked pricing gains support growth and cash flow improvement.

Personalis (PSNL) delivered earnings and revenue surprises of -20.00% and +30.21%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

FREMONT, Calif., August 04, 2026--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the second quarter ended June 30, 2026, and highlighted recent business accomplishments.

In the past week, Tempus AI, Inc. reported second-quarter 2026 results showing revenue of US$382.49 million and a swing from a net loss of US$42.84 million a year ago to net income of US$5.64 million, while also raising its full-year 2026 revenue outlook to between US$1.60 billion and US$1.61 billion. Alongside this performance, Tempus AI advanced its oncology and data ambitions through the planned acquisition of Personalis and highlighted growing diagnostics volume and new data...